Key result
Catheter ablation shows potential benefit in cardiac amyloidosis despite high arrhythmia recurrence rates.
Why the study?
Patients with cardiac amyloidosis often develop atrial arrhythmias but are considered poor candidates for catheter ablation due to infiltrative atrial substrates and high recurrence rates, and no meta-analysis has pooled efficacy and safety outcomes in this population.
Does catheter ablation improve efficacy and safety outcomes in patients with cardiac amyloidosis and atrial arrhythmias?
Does catheter ablation improve efficacy and safety outcomes in patients with cardiac amyloidosis and atrial arrhythmias?
This study aims to synthesize data on the safety and efficacy of catheter ablation in patients with cardiac amyloidosis who develop atrial arrhythmias.
High recurrence (45%) and mortality after ablation in CA warrant careful selection; leaves open need for RCTs before broader adoption.
Patients with cardiac amyloidosis (CA) often develop atrial arrhythmias but are considered poor ablation candidates due to infiltrative atrial substrates and high recurrence rates. Emerging data suggest potential benefits despite arrhythmia recurrence. No meta-analysis has pooled efficacy and safety outcomes in this population.
No takes yet. Share an insight, caveat, or question.
Bandaru et al. (2026) studied this question. Catheter ablation in cardiac amyloidosis may offer potential benefits despite high arrhythmia recurrence rates, though pooled safety and efficacy outcomes are currently lacking.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: